Findings showed 21% of patients treated with tralokinumab achieved an IGA score of 0 or 1 at week 16 compared with 4% of those who received placebo. The Food and Drug Administration (FDA) has expanded ...
The new single-dose autoinjector is available in a 300mg/2mL dosage strength and is intended for use in adults only. The Food and Drug Administration (FDA) has approved a new single-dose autoinjector ...
MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, will present a catalog of investigational delgocitinib cream and Adbry ® data across 10 posters at the upcoming ...
ADBRY ® (tralokinumab-ldrm) injection is a prescription medicine used to treat people 12 years of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with ...
ADBRY ® (tralokinumab-ldrm) injection is a prescription medicine used to treat people 12 years of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results